Goals
• Define whether systems biology offers major improvements in the safety evaluation of new chemical entities with indications in oncology
• Discuss where it adds value, how it could be implemented, what its limitations are
• Determine whether guidance documentation is needed to help accelerate the adoption of systems biology for regulatory science Systems Biology
• Elucidation of the complex interactions of a biological system and how it gives rise to the function or loss of function of a system  Holistic rather than reductionist  Combines biological, pharmacological, molecular and biochemical properties of a system  Moves away from one target, one outcome  Defines the interactions of the system components Technologies making systems biology a reality
• High density arrays -Genomics, transcriptomics…
• Mass spectrometry and NMR -Metab(an)olomics, glycomics, lipidomics..
• Questions for the Panel
• Are current animal testing methods insufficient?
• Are the issues correctly defined and phased?
• What changes to the current testing paradigm will have the biggest impact?
• Is systems biology sufficiently developed to add value?
• Has understanding the MOA helped? Does it influence regulatory decision making?
• What needs to be done to implement incorporation?
• How can industry, academia and govt work together to define principles of application and foster implementation? In 2000, the National Toxicology Program determined that saccharin should no longer be listed as a potential cancer-causing agent.
Creating Opportunity in the "Valley of Death"
• VoD is the gulf between discovering a promising new drug and demonstrating its effectiveness in humans • Preclinical drug discovery accounts for 32% of the costs of developing a drug • 8% of NMEs will make it from preclinical selection to launch. Therefore,12 products are needed in the preclinical development phase for one successful NME launch 
